SMARCA2

Across TCGA pan-cancer cohorts, SMARCA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SMARCA2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMARCA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMARCA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where SMARCA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.366	1.000	.016	18	view →
LUAD	DFS	Median	All	0.738	0.486	.005	7	view →
PDAC	DFS	Quartile	All	0.911	0.733	.012	6	view →
HNSC	OS	Quartile	All	0.766	0.902	.023	3	view →
GBM	OS	Quartile	All	0.495	0.306	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SMARCA2–UCEC (DFS)

Open the UCEC breakdown →